Business
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients. Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO, stated, “IDS is an important forum for us to present the breadth of SAB-142's clinical and mechanistic profile. We are pleased to share data on SAB-142's multi-specific binding profile and additional C-peptide data from our patient cohort, which we believe underpins its best-in-class potential. With the SAFEGUARD study now actively enrolling, we look forward to continued engagement with the T1D scientific community as we advance toward our anticipated topline data readout for this study in the 2H 2027.” Oral Presentation: Title: Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance DosingSession: SAB BIO Industry SymposiumPresenters: John Wentworth, PhD, FRACP, Professor of Medicine*, Alexandra Kropotova, MD, MBA, Chief Medical Officer, SAB BIO; Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIOPresentation Date and Time: Wednesday, April 22, 2026 | 1:00 – 1:45PM AESTLocation: Boulevard Auditorium*Dr. Wentworth is an independent guest speaker and is not affiliated with SAB BIO. Oral Poster Presentations:Title: Multi-specific binding profile of SAB-142, a fully human anti-thymocyte globulin, against T-cell surface proteinsSession: Poster Session 1 – Poster #207Presenter: Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIOPresentation Date and Time: Tuesday, April 21, 2026 | 5:30 – 7:00PM AESTLocation: Boulevard Foyer Title: Tracking multiplicity for SAB142: a PBMC based flow cytometry pharmacokinetic assay linking target engagement to clinical exposureSession: Poster Session 1 – Poster #264Presenter: Eric Sandhurst, PhD, Director, Program Management, SAB BIOPresen...